Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.

Belousova N, Mikheeva G, Xiong C, Stagg LJ, Gagea M, Fox PS, Bassett RL, Ladbury JE, Braun MB, Stehle T, Li C, Krasnykh V.

Oncotarget. 2016 Aug 16;7(33):53414-53429. doi: 10.18632/oncotarget.10800.

2.

Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.

Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grütter MG, Belousova N, Mikheeva G, Krasnykh V, Plückthun A.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E869-77. doi: 10.1073/pnas.1213653110. Epub 2013 Feb 19.

3.

Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.

Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L 2nd, Young D, Volgin AY, Najjar AM, Krasnykh V, Tong W, Alauddin MM, Gelovani JG.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1603-8. doi: 10.1073/pnas.1010744108. Epub 2011 Jan 10.

4.

Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.

Dreier B, Mikheeva G, Belousova N, Parizek P, Boczek E, Jelesarov I, Forrer P, Plückthun A, Krasnykh V.

J Mol Biol. 2011 Jan 14;405(2):410-26. doi: 10.1016/j.jmb.2010.10.040. Epub 2010 Nov 5.

5.

Development of a targeted gene vector platform based on simian adenovirus serotype 24.

Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L, Naff K, Bidaut L, Wei W, Li C, Gelovani J, Krasnykh V.

J Virol. 2010 Oct;84(19):10087-101. doi: 10.1128/JVI.02425-09. Epub 2010 Jul 14.

6.

A strategy for adenovirus vector targeting with a secreted single chain antibody.

Glasgow JN, Mikheeva G, Krasnykh V, Curiel DT.

PLoS One. 2009 Dec 21;4(12):e8355. doi: 10.1371/journal.pone.0008355.

7.

Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.

Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J.

Cancer Gene Ther. 2009 Mar;16(3):256-65. doi: 10.1038/cgt.2008.75. Epub 2008 Oct 17.

8.

Therapeutic Molecular Targetingof 15-Lipoxygenase-1 in Colon Cancer.

Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I.

Mol Ther. 2008 May;16(5):886-892. doi: 10.1038/mt.2008.44. Epub 2016 Dec 8.

PMID:
28178489
9.

Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.

Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I.

Mol Ther. 2008 May;16(5):886-92. doi: 10.1038/mt.2008.44. Epub 2008 Mar 18.

10.

Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer.

Belousova N, Mikheeva G, Gelovani J, Krasnykh V.

J Virol. 2008 Jan;82(2):630-7. Epub 2007 Nov 7.

11.

Cell cycle arrest and apoptosis induced by SART-1 gene transduction.

Hosokawa M, Kadota R, Shichijo S, Itoh K, Dmitriev I, Krasnykh V, Curiel DT, Takue Y, Wakasugi H, Takashima S, Heike Y.

Anticancer Res. 2005 May-Jun;25(3B):1983-90.

12.

Identification of sites in adenovirus hexon for foreign peptide incorporation.

Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT.

J Virol. 2005 Mar;79(6):3382-90.

13.

Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer.

Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, Krasnykh VN, Kunisaki C, Shimada H, Curiel DT, Yamamoto M.

J Gastroenterol. 2005 Jan;40(1):31-42.

PMID:
15692787
14.

Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery.

Wang M, Hemminki A, Siegal GP, Barnes MN, Dmitriev I, Krasnykh V, Liu B, Curiel DT, Alvarez RD.

Gynecol Oncol. 2005 Feb;96(2):341-8.

PMID:
15661219
15.

Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.

Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM.

Gene Ther. 2004 Dec;11(23):1694-702.

PMID:
15496964
16.

Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus.

Zinn KR, Szalai AJ, Stargel A, Krasnykh V, Chaudhuri TR.

Gene Ther. 2004 Oct;11(19):1482-6.

PMID:
15295616
17.

Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.

Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M.

Cancer Res. 2004 Jun 15;64(12):4319-27.

18.

HSV-1 virions engineered for specific binding to cell surface receptors.

Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO.

Mol Ther. 2004 Mar;9(3):419-27.

19.
20.

Adenovirus-mediated gene delivery to dendritic cells.

Timares L, Douglas JT, Tillman BW, Krasnykh V, Curiel DT.

Methods Mol Biol. 2004;246:139-54.

PMID:
14970589
21.

Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.

Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, Pereboev A, Kotov A, Kotova O, Triozzi PL, Aldrich WA, Douglas JT, Lo KM, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V.

J Virol. 2003 Dec;77(24):12931-40.

22.

Genetically targeted adenovirus vector directed to CD40-expressing cells.

Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL, Aldrich WA, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V.

J Virol. 2003 Nov;77(21):11367-77.

23.

Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.

Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT.

Gastroenterology. 2003 Oct;125(4):1203-18.

PMID:
14517802
24.

Approaches to utilize mesenchymal progenitor cells as cellular vehicles.

Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT.

Stem Cells. 2003;21(4):389-404.

25.

The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells.

Kim M, Sumerel LA, Belousova N, Lyons GR, Carey DE, Krasnykh V, Douglas JT.

Br J Cancer. 2003 May 6;88(9):1411-6.

26.

A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism.

Takayama K, Reynolds PN, Short JJ, Kawakami Y, Adachi Y, Glasgow JN, Rots MG, Krasnykh V, Douglas JT, Curiel DT.

Virology. 2003 May 10;309(2):282-93.

27.

Blood-based screening and light based imaging for the early detection and monitoring of ovarian cancer xenografts.

Chaudhuri TR, Cao Z, Krasnykh VN, Stargel AV, Belousova N, Partridge EE, Zinn KR.

Technol Cancer Res Treat. 2003 Apr;2(2):171-80.

PMID:
12680799
28.

Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement.

Nagi P, Vickers SM, Davydova J, Adachi Y, Takayama K, Barker S, Krasnykh V, Curiel DT, Yamamoto M.

J Gastrointest Surg. 2003 Mar-Apr;7(3):364-71.

PMID:
12654561
29.

Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.

Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT, Blackwell JL.

Cancer Res. 2003 Mar 15;63(6):1262-9.

30.

Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein.

Sullivan DE, Mondelli MU, Curiel DT, Krasnykh V, Mikheeva G, Gaglio P, Morris CB, Dash S, Gerber MA.

J Hepatol. 2002 Nov;37(5):660-8.

PMID:
12399234
31.

The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells.

Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT.

Eur J Cancer. 2002 Sep;38(14):1917-26.

PMID:
12204675
32.

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V.

J Virol. 2002 Sep;76(17):8621-31.

33.

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT.

Cancer Res. 2002 Aug 1;62(15):4273-81.

34.

Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice.

Zinn KR, Chaudhuri TR, Krasnykh VN, Buchsbaum DJ, Belousova N, Grizzle WE, Curiel DT, Rogers BE.

Radiology. 2002 May;223(2):417-25.

PMID:
11997547
35.

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A.

Cancer Res. 2002 Mar 1;62(5):1266-70.

36.

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT.

Clin Cancer Res. 2002 Jan;8(1):275-80.

37.

Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors.

Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, Dmitriev I.

Gene Ther. 2001 Jul;8(13):969-76.

38.

Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells.

Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, Bergelson JM, Currier MA.

Cancer Res. 2001 Apr 1;61(7):2953-60.

39.

Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin.

Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT.

J Virol. 2001 May;75(9):4176-83.

40.

Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells.

Asada-Mikami R, Heike Y, Kanai S, Azuma M, Shirakawa K, Takaue Y, Krasnykh V, Curiel DT, Terada M, Abe T, Wakasugi H.

Jpn J Cancer Res. 2001 Mar;92(3):321-7.

41.

A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.

Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R.

Clin Cancer Res. 2001 Jan;7(1):120-6.

42.

Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity.

Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, Douglas JT, Curiel DT.

Cancer Res. 2000 Dec 15;60(24):6784-7. Review.

43.

Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.

Blackwell JL, Li H, Gomez-Navarro J, Dmitriev I, Krasnykh V, Richter CA, Shaw DR, Alvarez RD, Curiel DT, Strong TV.

Hum Gene Ther. 2000 Aug 10;11(12):1657-69.

PMID:
10954900
44.

Genetic targeting of adenoviral vectors.

Krasnykh VN, Douglas JT, van Beusechem VW.

Mol Ther. 2000 May;1(5 Pt 1):391-405. Review. No abstract available.

46.

Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.

Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, Kropf DA, Carroll WR, Peters GE, Bucy RP, Curiel DT, Krasnykh V.

Clin Cancer Res. 1999 Sep;5(9):2571-9.

47.

Reduction of ischemia-reperfusion injury of the liver by in vivo adenovirus-mediated gene transfer of the antiapoptotic Bcl-2 gene.

Bilbao G, Contreras JL, Eckhoff DE, Mikheeva G, Krasnykh V, Douglas JT, Thomas FT, Thomas JM, Curiel DT.

Ann Surg. 1999 Aug;230(2):185-93.

48.

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.

Vanderkwaak TJ, Wang M, Gómez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R, Curiel DT.

Gynecol Oncol. 1999 Aug;74(2):227-34.

PMID:
10419736
49.

Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene.

Bilbao G, Contreras JL, Zhang HG, Pike MJ, Overturf K, Mikheeva G, Krasnykh V, Curiel DT.

J Virol. 1999 Aug;73(8):6992-7000.

50.

A system for the propagation of adenoviral vectors with genetically modified receptor specificities.

Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V, Curiel DT.

Nat Biotechnol. 1999 May;17(5):470-5.

PMID:
10331807

Supplemental Content

Loading ...
Support Center